Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.

[1]  C. Boland,et al.  Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer , 2011, Annals of Internal Medicine.

[2]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[3]  J. Hopper,et al.  Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. , 2011, The Journal of molecular diagnostics : JMD.

[4]  Vikas Bansal,et al.  Efficient and Cost Effective Population Resequencing by Pooling and In-Solution Hybridization , 2011, PloS one.

[5]  C. Huttenhower,et al.  Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. , 2010, The American journal of pathology.

[6]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Ulrich,et al.  Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. , 2010, Journal of the National Cancer Institute.

[8]  R. Palmqvist,et al.  The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status , 2010, Clinical Cancer Research.

[9]  F. Sinicrope.  DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer , 2010, Nature Reviews Clinical Oncology.

[10]  Heather Hampel,et al.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer , 2010, Genetics in Medicine.

[11]  P. Laird,et al.  Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling , 2009, PloS one.

[12]  N. Cho,et al.  Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers , 2009, Virchows Archiv.

[13]  Laura H. Tang,et al.  Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.

[14]  Jukka-Pekka Mecklin,et al.  Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Hollema,et al.  Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome , 2009, Genes, chromosomes & cancer.

[16]  P. A. van den Brandt,et al.  MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Gulley,et al.  CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. , 2009, The Journal of molecular diagnostics : JMD.

[18]  Shuji Ogino,et al.  DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer , 2009, Clinical Cancer Research.

[19]  N. Matsubara,et al.  Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. , 2009, Oncology reports.

[20]  O. Dominic,et al.  American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2009, The American Journal of Gastroenterology.

[21]  Douglas K Rex,et al.  American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2022 .

[22]  S. Gruber,et al.  Pathologic Predictors of Microsatellite Instability in Colorectal Cancer , 2009, The American journal of surgical pathology.

[23]  John Quackenbush,et al.  Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample , 2008, PloS one.

[24]  J. Jiricny,et al.  Mechanisms of pathogenicity in human MSH2 missense mutants , 2008, Human mutation.

[25]  P. Laurent-Puig,et al.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. , 2008, Cancer research.

[26]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[27]  Robert Brown,et al.  CpG island methylator phenotype (CIMP) in cancer: causes and implications. , 2008, Cancer letters.

[28]  E. Steyerberg,et al.  Phenotype Comparison of MLH1 and MSH2 Mutation Carriers in a Cohort of 1,914 Individuals Undergoing Clinical Genetic Testing in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.

[29]  M. Ligtenberg,et al.  Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting , 2008, The American journal of surgical pathology.

[30]  M. Ebert,et al.  Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC , 2008, European Journal of Human Genetics.

[31]  D. English,et al.  Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype , 2008, Cancer Epidemiology Biomarkers & Prevention.

[32]  J. Shia.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. , 2008, The Journal of molecular diagnostics : JMD.

[33]  D. Evans,et al.  Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations , 2008, Clinical genetics.

[34]  M. Kloor,et al.  Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. , 2008, Gastroenterology.

[35]  M. Nilbert,et al.  Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers. , 2008, American journal of clinical pathology.

[36]  B. Bellosillo,et al.  A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  N. Cho,et al.  Clinicopathological features of CpG island methylator phenotype‐positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation , 2008, Pathology international.

[38]  P. Propping,et al.  Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome , 2008, The Journal of pathology.

[39]  R. Jaenisch,et al.  Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. , 2007, Genes & development.

[40]  John D Potter,et al.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. , 2007, Gastroenterology.

[41]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[42]  L. Aaltonen,et al.  No evidence for dual role of loss of heterozygosity in hereditary non-polyposis colorectal cancer , 2007, Oncogene.

[43]  P. Møller,et al.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.

[44]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[45]  M. O'brien,et al.  Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points , 2006, The American journal of surgical pathology.

[46]  G. Petersen,et al.  Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. , 2006, JAMA.

[47]  A. Cats,et al.  What is the appropriate screening protocol in Lynch syndrome? , 2006, Familial Cancer.

[48]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[49]  Harry Campbell,et al.  Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. , 2006, The New England journal of medicine.

[50]  R. Gafà,et al.  Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  W. Foulkes,et al.  Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis , 2006, Gut.

[52]  R. Gafà,et al.  Microsatellite Instability and Colorectal Cancer Prognosis , 2005, Clinical Cancer Research.

[53]  J. Cubiella,et al.  Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer , 2005, Gut.

[54]  A. Krasinskas,et al.  Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability. , 2005, Archives of pathology & laboratory medicine.

[55]  John L Hopper,et al.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[57]  J. Jass.  Serrated adenoma of the colorectum and the DNA-methylator phenotype , 2005, Nature Clinical Practice Oncology.

[58]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[59]  Hiroyuki Yamamoto,et al.  BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes , 2005, Oncogene.

[60]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[61]  M. Andreu,et al.  Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. , 2005, JAMA.

[62]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  L. Aaltonen,et al.  Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. , 2004, Human molecular genetics.

[64]  L. Aaltonen,et al.  BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.

[65]  N. Matsubara,et al.  BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum , 2004, Gut.

[66]  H. Morreau,et al.  Survival after adjuvant 5‐FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer , 2004, International journal of cancer.

[67]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[68]  C. Behling,et al.  Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. , 2004, Gastroenterology.

[69]  Y. Yamashita,et al.  Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas , 2004, International journal of cancer.

[70]  G. Deng,et al.  BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[71]  G. Taylor,et al.  Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non‐polyposis colorectal cancer: Identification of novel and recurrent deletions by MLPA , 2003, Human mutation.

[72]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[73]  Yan P. Yuan,et al.  Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes , 2003, Oncogene.

[74]  C. Compton,et al.  Characterization of sporadic colon cancer by patterns of genomic instability. , 2003, Cancer research.

[75]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[76]  B. Leggett,et al.  Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. , 2001, The American journal of pathology.

[77]  W. Zoller,et al.  [Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer]. , 2001, Zeitschrift fur Gastroenterologie.

[78]  D. Schaid,et al.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. , 2001, American journal of human genetics.

[79]  M. Leppert,et al.  Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[80]  L. Roncucci,et al.  Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer , 2001, Genes, chromosomes & cancer.

[81]  M. Southey,et al.  Molecular Pathologic Analysis Enhances the Diagnosis and Management of Muir-Torre Syndrome and Gives Insight Into Its Underlying Molecular Pathogenesis , 2001, The American journal of surgical pathology.

[82]  B. Leggett,et al.  Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer , 2000, The British journal of surgery.

[83]  B. Leggett,et al.  DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer , 2000, Gut.

[84]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  A. de la Chapelle,et al.  Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. , 2000, The American journal of pathology.

[86]  Carolyn Compton,et al.  American Joint Committee on Cancer prognostic factors consensus conference , 2000, Cancer.

[87]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[88]  D. Schaid,et al.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. , 1999, Journal of the National Cancer Institute.

[89]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[90]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[91]  S. Baylin,et al.  Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. , 1999, Cancer research.

[92]  B. Leggett,et al.  DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? , 1999, Journal of clinical pathology.

[93]  P. Møller,et al.  MSH2 genomic deletions are a frequent cause of HNPCC , 1998, Nature Genetics.

[94]  S N Thibodeau,et al.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. , 1998, Cancer research.

[95]  T. Smyrk,et al.  Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members , 1998, Cancer.

[96]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[97]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[98]  R. Farber,et al.  Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair , 1998, Oncogene.

[99]  M. Ballegooijen,et al.  A cost‐effectiveness analysis of colorectal screening for hereditary nonpolyposis colorectal carcinoma gene carriers , 1998, Cancer.

[100]  D. Schaid,et al.  Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. , 1998, Cancer research.

[101]  J. P. Dunn.  Colorectal cancer screening. , 1997, The New Zealand medical journal.

[102]  J. Rüschoff,et al.  Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. , 1997, Cancer research.

[103]  D. Shibata,et al.  DNA mismatch repair in mammals: role in disease and meiosis. , 1997, Current opinion in genetics & development.

[104]  S. Bülow,et al.  Hereditary non-polyposis colorectal cancer: clinical features and survival. Results from the Danish HNPCC register. , 1997, Scandinavian journal of gastroenterology.

[105]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[106]  S. Srivastava,et al.  National Cancer Institute Workshop on Genetic Screening for Colorectal Cancer. , 1996, Journal of the National Cancer Institute.

[107]  L. Aaltonen,et al.  Better survival rates in patients with MLH1-associated hereditary colorectal cancer. , 1996, Gastroenterology.

[108]  P. Karran,et al.  Microsatellite instability and DNA mismatch repair in human cancer. , 1996, Seminars in cancer biology.

[109]  L. Aaltonen,et al.  Life‐time risk of different cancers in hereditary non‐polyposis colorectal cancer (hnpcc) syndrome , 1995, International journal of cancer.

[110]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[111]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[112]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[113]  C. Boland,et al.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. , 1993, Gastroenterology.

[114]  G. Thomas,et al.  [Genetic predisposition to colorectal cancer]. , 1993, Annales de gastroenterologie et d'hepatologie.

[115]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[116]  L. Melton,et al.  Predictors of survival after curative resection of carcinoma of the colon and rectum , 1987, Cancer.

[117]  J. Stockman,et al.  Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer: A Cost-Effectiveness Analysis , 2013 .

[118]  L. Tanoue.  Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .

[119]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[120]  D. Snover.  Update on the serrated pathway to colorectal carcinoma. , 2011, Human pathology.

[121]  S. Woolf,et al.  Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995 64(6):430-3. PMID: 8550246 , 2011 .

[122]  S. Gruber,et al.  NCCN clinical practice guidelines in oncology. Colorectal cancer screening. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[123]  Monica R McClain,et al.  EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome , 2009, Genetics in Medicine.

[124]  M. Kloor,et al.  Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers. Authors' reply , 2008 .

[125]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.

[126]  Z. Gatalica,et al.  Pathology of the hereditary colorectal carcinoma , 2007, Familial Cancer.

[127]  M. Kloor,et al.  Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer , 2006, International journal of cancer.

[128]  S. Thibodeau,et al.  Use of Microsatellite Instability and Immunohistochemistry Testing for the Identification of Individuals at Risk for Lynch Syndrome , 2004, Familial Cancer.

[129]  B. Leggett,et al.  Promoter Hypermethylation Frequency and BRAF Mutations Distinguish Hereditary Non-Polyposis Colon Cancer from Sporadic MSI-H Colon Cancer , 2004, Familial Cancer.

[130]  J. Kładny,et al.  Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. , 2000, European journal of cancer.

[131]  J. Mecklin,et al.  Prognosis of colorectal cancer varies in different high-risk conditions. , 1998, Annals of medicine.

[132]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[133]  R. Fitzgibbons,et al.  Hereditary Colorectal Cancer , 1990, Springer Japan.

[134]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[135]  Jeffrey R. Botkin,et al.  Summary of Recommendations: The Evaluation of Genomic Applications , 2022 .